Skip Ribbon Commands
Skip to main content
Menu

Current Clinical Trials

For enquiries, please email clinical.trials@nccs.com.sg

Phase 1


No Site​ ​Stage of cancer Title of study ​Principal investigator ​Details of trial ​Status
​1​CRC, Ovarian & Endometrial​IV

​D3-002
A Phase 1A/B study to evaluate the safety and tolerability of ET-1922159 in advanced solid tumours

​Dr Matthew Ng NCT02521844 ​Open
2Epithelial sarcoma, NPC, Gastric, Prostate Ovarian & DLBCLIV​CMAK683X2101
A Phase I/II, multicenter, open-label study of MAK683 in adult patients with advanced malignancies
​Dr Daniel Tan NCT02900651​On hold
​3NSCLC, Melanoma, all solid tumors except CRC IV​CTNO155X2101
An Open-label, multi-center, Phase I, dose finding study of oral TNO155 in adult patients with advanced solid tumors
​Dr Daniel TanNCT03114319​Open
​4​​CRC and PDAC​​Advanced​CTMT212XSG01T
Phase Ib study evaluating safety and tolerability of combination trametinib and ruxolitinib in patients with advanced RAS mutant colorectal cancer and pancreatic adenocarcinoma
​Dr David TaiNCT04303403​Open
​5​​Lung​​LOCALLY ADVANCED/ METASTATIC - First LineCPDR001C2101
Phase 1b, multicenter, open label, 3 arm, dose de-escalation study of PDR001 in combination with platinum-doublet chemotherapy in 1st line, PD-L1 unselected, NSCLC patients
​Dr Daniel TanNCT03064854​Open
6​​All Solid Tumour​documented RET infusionLOXO-RET-17001
A Phase 1 Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, and Other Tumors with Increased RET Activity
​Dr Daniel TanNCT03157128​Open
7NSCLC, Pancreas and all solid tumors ​IVMCLA-128-CL01
A Phase I/II Study of MCLA-128, a full length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors
​Dr Justina Lam NCT02912949​Open
8​All Solid Tumour with documented NTRK fusions ​must had prior TRK inhibitorLOXO-EXT-17005
A Phase 1/2 study of the TRK Inhibitor LOXO-195 in Adult and Pediatric Subjects with Previously Treated NTRK fusion cancers
​Dr Daniel Tan NCT03215511Open
9NSCLC, TNBC, PDAC, RCC, Ovarian, CRC, Prostate​IVCNZV930X2101
A Phase I/Ib, open-label, multi-center study of NZV930 as a single agent and in combination with PDR001 and/or NIR178 in patients with advanced malignancies
Dr Koo Si-Lin NCT03549000​Open
10​NSCLC​​with documented EGFR Exon 20 insertion mutation CLN-081-001
 A Phase 1/2a, Open-Label, Multi-Center Trial to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CLN-081 in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
​Dr Daniel TanNCT04036682On hold
11​Prostate​​Advanced recurrentAmgen 20180101
 A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Prostate Specific Membrane Antigen Half-life Extended Bispecific T-cell Engager AMG 160 in Subjects With Metastatic Castration-resistant Prostate Cancer
​Dr Daniel TanNCT03792841​On hold
12​​All Solid Tumour​documented RET infusionLIBRETTO-201
A Multi-Center Expanded Access Program (EAP) for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors with Rearranged During Transfection (RET) Activation
​Dr Daniel TanNCT03906331Open
13​All Solid Tumour​​​Advanced recurrentTHOR-707-101
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and in a Combination Therapy in Adult Subjects with Advanced or Metastatic Solid Tumors
​Dr Tira TanNCT04009681Open
14
​All Solid Tumour​​Advanced recurrentTAPISTRY
Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational For You (TAPISTRY) Phase II Platform Trial
​Dr Tira TanNCT04589845Open
15
NSCLC, CRC​​Advanced recurrentCJDQ443A12101
A phase Ib/II open-label, multi-center dose escalation study of JDQ443 in advanced solid tumor patients harboring the KRAS G12C mutation
​​​Dr Daniel Tan​NCT04699188​Open
16
​NSCLC​​Advanced recurrentDESTINY-Lung03
A Phase Ib Multicenter, Open-label Dose-escalation Study to Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan (T-DXd) and Durvalumab in Combination with Cisplatin, Carboplatin or Pemetrexed in First-line Treatment of Patients with Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) and Human Epidermal Growth Factor Receptor 2 Overexpression (HER2+) (DESTINY-Lung03)
​Dr Stephanie SawNCT04686305​Open
​17
​NSCLC​​Advanced recurrentBayer 21607
An open label, first-in-human study of BAY 2927088 in participants with advanced non-small cell lung cancer (NSCLC) harboring an EGFR and/or HER2 mutation
​Dr Daniel TanNCT05099172​Open
18
​NSCLC​​Advanced recurrentBLU-945-1101
A Phase 1/2 Study Targeting Acquired Resistance Mechanisms in Patients with EGFR Mutant Non-Small Cell Lung Cancer
​Dr Daniel TanNCT04862780​Open
19
​Gastric ​Metastatic gastric cancer with peritoneal metsPIANO (CA209-7HC)
Phase 1 Study of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with oxaliplatin and in combination with Nivolumab in patients with peritoneal carcinomatosis
​Dr Claramae ChiaNCT03172416​Open
20
​ccRCC and HCC​​Advanced recurrentSRF388-101
A Phase 1 Study of SRF388 in Patients with Advanced Solid Tumors
​Dr Toh Han ChongNCT04374877​On hold
21
​Cholangio and all soild tumors​with FGFR2 mutationRLY-4008-101
A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With Intrahepatic Cholangiocarcinoma (ICC) and Other Advanced Solid Tumors Cancers
​Dr David TaiNCT04526106​Open
​22
​NSCLC
HNSCC
Urothelial
​​Advanced recurrentBAYER 21343
An open-label, Phase 1b, dose escalation and expansion study to evaluate the safety, tolerability, maximum tolerated or administered dose, pharmacokinetics, pharmacodynamics and efficacy of the Aryl Hydrocarbon Receptor inhibitor (AhRi) BAY 2416964 in combination with pembrolizumab in participants with advanced solid tumors
​​Dr Daniel TanNCT04999202​On hold
​23
​​All Solid Tumour​​Advanced recurrentADG116-1003
A Phase 1, Open-Label, Dose Escalation and Expansion Study of ADG116, ADG116 Combined with ADG106 (Anti-CD137 Antibody), ADG116 Combined with Toripalimab
(Anti-PD-1 Antibody) in Patients with Advanced/Metastatic
Solid Tumors
​Dr Matthew NgNCT04501276​Open
24
Breast and Gastric
with HER2+GO40311
A PHASE Ia/b, OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF BTRC4017A ADMINISTERED INTRAVENOUSLY AS A SINGLE AGENT AND IN COMBINATION WITH TRASTUZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC HER2-EXPRESSING CANCERS
Dr Tira TanNCT03448042
Open

 

Current clinical trials by body parts

No Site​ ​Stage of cancer ​Title of study ​Principal investigator Details of trial Status
1​Bladder​Unresectable or Metastatic Urothelial CancerCA209-901
A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab, or with Standard of Care Chemotherapy, versus Standard of Care Chemotherapy in Participants with Previously Untreated Unresectable or Metastatic Urothelial Cancer
​Dr Ravindran Kanesvaran NCT03036098​Open
2​​BladderNeoadjuvant and adjuvant chemotherpay for non-muscle invasive bladder cancerCA017-078
A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post-Surgery Therapy with Nivolumab or Nivolumab and BMS-986205 in Participants  with Muscle-Invasive Bladder Cancer
​Dr Ravindran KanesvaranNCT03661320​Open
​3​Bladder​locally advanced or metastatic urothelial cancerSGN22E-003/EV-302
An open- label, randomized, controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab versus chemotherapy alone in previously untreated locally advanced or metastatic urothelial cancer
​Dr Ravindran KanesvaranNCT04223856​Open
4​Breast ​MetastaticBEXMET
Metastatic Triple-Negative Taxane-Resistant Breast Cancer: Investigating the Role of Bexarotene in Inducing Susceptibility to Chemotherapy by Differentiating Cancer Cells from a Mesenchymal-Like to an Epithelial-Like Phenotype
​Dr Elaine Lim​NCT04664829​Open
5
​BreastPIK3 CA-Mutant HR+, HER2 - LABC/MBCWO41554
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GDC 0077 Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant In Patients with Locally Advanced or Metastatic Pik3ca-Mutant Hormone Receptor-Positive, Her2 Negative Breast Cancer
Dr Yap Yoon Sim NCT04191499       ​Open
6
​Breast ​Adjuvant / Metastatic TCF20-BRE-01
An open-label, single-institution, dose-determining (Part I) and dose-confirmatory (Part II) study to investigate the optimal dose of Tamoxifen in breast cancer patients harboring different TCF20 rs932376 variant alleles
​Dr Elaine LimNCT04961632​Open
7
​Breast​TNBCWO39391-IMPASSION 030
A Phase III, Multicenter, Randomized, Open-label Study Comparing ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) In Combination With Standard Adjuvant ANTHRACYCLINE/TAXANE-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable TRIPLE-NEGATIVE Breast Cancer
​Dr Rebecca DentNCT03498716​Open
8
​Breast​HER2+ AdjWO42633-Astefania:
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Atezolizumab or Placebo in Combination with Trastuzumab Emtansine as Adjuvant Therapy for Patients with HER2-Positive Primary Breast Cancer At Risk of Recurrence Who have Residual Tumor Present Pathologically in the Breast and/or Axillary Lymph Nodes Following Preoperative Therapy
​Dr Yap Yoon SimNCT04873362​Open
9
​Breast​HER2 +DESTINY-Breast05:
A Phase 3, multicenter, randomized, open-label, active-controlled study of trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in subjects with high-risk HER2positive primary breast cancer who have residual invasive disease in breast or axillary lymph nodes following neoadjuvant therapy
​Dr Tira TanNCT04622319​Open
10
​Breast​Mets TNBC

D9670C00001: DESTINY-Breast06:

A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator’s Choice Chemotherapy in HER2-low, Hormone Receptor Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting

​Dr Rebecca DentNCT04494425​Open
11
​Breast​Mets TNBC

MO39193-IMPASSION 132:

Phase III, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of the Efficacy and Safety of Atezolizumab in Combination with Chemotherapy for Patients with Early Relapsing Recurrent (Inoperable Locally Advanced or Metastatic) Triple-Negative Breast Cancer

​Dr Rebecca DentNCT03371017​Open
12​Colorectal​NeoadjuvantOTSP-WoOCRC / MK-3475-886
Window of Opportunity Study with Neoadjuvant Pembrolizumab in MSS & MSI Colorectal Cancer
​Dr Iain Tan NCT03984578​Open
13​Colorectal​Advance 2nd lineMirati 849-010/KRYSTAL-10
A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy
​Dr Dawn ChongNCT04793958​Open
​14
​Esophageal
​Unresectable Locally Advanced, Unresectable Recurrent,  Metastatic, 1st line
YO42138
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Of Atezolizumab Plus Tiragolumab In Combination With Paclitaxel And Cisplatin Compared With Paclitaxel And Cisplatin As First-Line Treatment In Patients With Unresectable Locally Advanced, Unresectable Recurrent, Or Metastatic Esophageal Squamous Cell Carcinoma
​Dr Matthew Ng
NCT04540211
​Open
15
​Gastric GEJ
​Advanced 2nd lineDS8201-A-U306
A Phase 3, multicenter, 2-arm randomized, open-label study of trastuzumab deruxtecan in subjects with HER2-positive advanced gastric or gastro-esophageal junction (GEJ) adenocarcinoma subjects who have progressed on or after a trastuzumab-containing regimen
​Dr Matthew NgNCT04704934​Open
16
​Gastric GEJ
​Advanced 2nd and 3rd line
ASPEN-06
A Phase 2/3 Study of ALX148 In Patients with Advanced HER2-Overexpressing Gastric/Gastroesophageal Junction Adenocarcinoma
​Dr Matthew Ng
NCT05002127
​Open
​17
​Gastric GEJ
​Advance 1st line
​FORTITIUDE-101
A Randomized, Multi-center, Double-blind, Placebo-controlled Phase 3 Study of Bemarituzumab plus Chemotherapy versus Placebo plus Chemotherapy in Subjects with Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer with FGFR2b Overexpression
​Dr Matthew Ng
NCT05052801
​Open
18
​Liver​Advance/ Metastatic  2nd lineCA224-073
A Phase 2, Randomized, Open-label Study of Relatlimab in Combination with Nivolumab in Participants with Advanced Hepatocellular Carcinoma who are Naive to IO Therapy but Progressed on Tyrosine Kinase Inhibitors
​Dr David TaiNCT04567615​Open
19
​​Liver​Neoadjuvant + adjuvant

NCCS-OTSP-HCC1 / MK-3475-750

Longitudinal Immune-phenotyping of Surgically Resected HCC following Neoadjuvant and Adjuvant Treatment with MK – 3475

​Dr Toh Han ChongNCT04224480​Open
20
​Liver​Adv 1st lineJS001-027-III-HCC
A prospective, randomized, placebo-controlled, double-blind, multicenter phase III registration clinical study to compare Toripalimab (JS001) combined with Lenvatinib versus placebo combined with Lenvatinib as the 1st-line therapy for advanced hepatocellular carcinoma (HCC)
​Dr Joycelyn LeeNCT04523493​Open
21
​Liver​AdjuvantCA209-7R9
An open label, single-arm, Phase II Neoantigen (NA) Dendritic Cell (DC) vaccine and anti-PD1 (Nivolumab) as adjuvant treatment in resected hepatocellular carcinoma (HCC) (Group A) and liver metastases from colorectal cancer (CRLM) (Group B)
​Dr Koo Si LinNCT04912765​Open
22
​Lung​LOCALLY ADVANCED/ METASTATIC - First Line ​BO29554
A Phase II/III Multicenter Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (B-FAST: Blood-First Assay Screening Trial)
​Dr Daniel Tan NCT03178552​Open
23
​Lung​​LOCALLY ADVANCED/ METASTATIC - First LineTAK-788-3001
A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non–Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
​Dr Tanujaa NCT04129502​Open
24
​Lung​locally advanced or metastatic, 1st lineATORG-0003
A Single-arm, Open-label, Phase 2 Study of Dacomitinib with or without dose titration for the first-line treatment of locally advanced or metastatic non-small cell lung cancer in subjects with an epidermal growth factor receptor (EGFR) activation mutation
​Dr Daniel TanNCT04027647​Open
25
​​Lung​LA NSCLCCA209-73L
A Phase 3, Randomized, Open-Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer (LA NSCLC)
​Dr Daniel TanNCT04026412​Open
26
​Lung​Mets NSCLCLIBRETTO-431 - J2G-MC-JZJC
A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing LOXO-292 to Platinum-Pemetrexed Chemotherapy Plus Investigator’s Choice of Pembrolizumab in Patients with Advanced, Treatment-Naïve RET Fusion-Positive Non-Small Cell Lung Cancer
​Dr Daniel TanNCT04194944​Open
27
​Lung​Mets NSCLCTROPION-LUNG01 / DS1062-A-U301
Phase 3 Randomized Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer without Actionable Genomic Alterations
​Dr Amit JainNCT04656652​Open
28
​Lung
​Mest NSCLC
KRYSTAL-12 
A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation
​Dr Ang Mei Kim
​NCT04685135
​Open
29
​ Lymphoma​Relapsed/Refractory DLBCL​A Randomized, Open-Label, Phase 3 Trial of Epcoritamab vs Investigator’s Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma​ Dr Miriam TaoNCT04628494 ​Open
30
​Lymphoma​Relapsed/Refractory EBV+ Lymphomas VT3996-202
An Open-Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Subjects with Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL-1)
​Dr Nagavalli SomsundaramNCT05011058​Open
31
​Nasopharyngeal

Metastatic or recurrent nasopharyngeal carcinoma

No more than 1 line

​​CA209-796
A phase II trial of Ipililumab in combination with nivolumab in patients with advanced nasopharyngeal carcinoma
​Dr Darren LimNCT03097939​Open
32
​Head and Neck

​ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA

 

First Line

ASPEN03 - AT148003
A PHASE 2 STUDY OF ALX148 IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA
​Dr Ang Mei KimNCT04675294​Open
​33
​Head and Neck
​ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA

First Line

ASPEN04 - AT148004
A PHASE 2 STUDY OF ALX148 IN COMBINATION WITH PEMBROLIZUMAB AND CHEMOTHERAPY IN PATIENTS WITH ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA
​Dr Ang Mei Kim
NCT04675333

​Open
34
​Ovarian​AdvancedEPIK-O: CBYL719K1230
A Phase III, multi-center, randomized, open-label, active-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib as compared to single agent cytotoxic chemotherapy, in participants with no germline BRCA mutation detected, platinum-resistant or refractory, high grade serous ovarian cancer.
​Dr Chay Wen YeeNCT04729387​Open
35
​Prostate​MetastaticXL184-315 (CONTACT-02)
A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with Metastatic Castration-Resistant Prostate Cancer
​Dr Ng Quan SingNCT04446117​Open
36
​Prostate​MetastaticBayer 20510:
A Phase 4, randomized, open-label, multicenter efficacy and safety study of standard dose of radium-223 dichloride vs. standard doses of novel anti-hormonal therapy (NAH) in patients with bone dominant metastatic castration resistant prostate cancer (mCRPC) progressing on/after one line of NAH
​Dr Ng Quan SingNCT04597125​Open
​37
​Prostate
​Metastatic
CAAA617C12301 - PSMAddition: 
An International Prospective Open-label, Randomized, Phase III Study comparing 177Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
​Dr Ravindran Kanesvaran
NCT04720157
​Open
38
​Renal
​Locally advanced / metastatic - 1st line
D5086C00001 (SAMETA):
A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study of Savolitinib plus Durvalumab versus Sunitinib and Savolitinib plus Durvalumab versus Durvalumab in Participants with MET-Driven, Unresectable and Locally Advanced, or Metastatic Papillary Renal Cell Carcinoma (PRCC)
​Dr Ravindran Kanesvaran
NCT05043090
​Open
39
​​SarcomaRecurrent​​Radical resection and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in the treatment of high risk recurrent retroperitoneal sarcoma
​​Dr Johnny OngNCT03792867​Open


General

​No Site​ ​Stage of cancer ​Title of study ​Principal investigator ​Details of trial ​Status
​1​SOLID TUMORS ​LOCALLY ADVANCED / METASTATIC - ANY LINE CLDK378A2X01B
An open-label, multi-center, Phase IV, roll-over study in patients with ALK positive malignancies who have completed a prior Novartis-sponsored certinib (LDK378) study and are judged by the investigator to benefit from continued treatment with ceritinib
​Dr Daniel Tan NCT02584933​Open
​2​SOLID TUMORS ​LOCALLY ADVANCED / METASTATIC - ANY LINELOXO-TRK-15002 (NAVIGATE)
A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors
​Dr Daniel Tan NCT02576431​Open
​3​SOLID TUMORS​​LOCALLY ADVANCED/ METASTATIC – 1st and 2nd Line OnwardsAPL10101 
Phase 1/2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
​Dr Gillianne LaiNCT03175224​Open
4​SOLID TUMORS​​LOCALLY ADVANCED/ METASTATIC – 1st and 2nd Line OnwardsTPX-0005-01
A Phase 1/2, Open-Label, Multi-Center, First-In-Human Study of the Safety, Tolerability, Pharmacokinetics and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 rearrangements (TRIDENT-1)
​Dr Darren LimNCT03093116Open
5
SOLID TUMORS
(currently only HCC and gastric cohorts are opened)

Advanced curatively unresectable solid tumors failing standard therapy.

HCC: must have failed at least 1 line of standard therapy

Gastric cancer: must have failed at least 2 line of standard therapy (inclusive of adjuvant treatment)

Other solid tumours: must have failed at least 1 line of standard therapy

NCCS-2018-Phase2-PRL3
An open label Phase II study of the efficacy and tolerability of PRL3-ZUMAB and predictive biomarkers in advanced solid tumours
​Dr Matthew NgNCT04118114​Open
​6
​​SOLID TUMORS​​Any solid tumors with peritoneal mets​Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) for Peritoneal Metastases​​Dr Claramae Chia​NCT04956068​Open
7
​SOLID TUMORS ​ADVANCED/ METASTATIC - 2nd LineSTCC-01
A phase II multi-centre study evaluating the efficacy of dacomitinib for patients with epidermal growth factor receptor (EGFR)-driven advanced solid tumours with low EGFR-AS1 lncRNA expression or other novel emerging biomarkers
​Dr Daniel TanNCT04946968Open